Trials / Completed
CompletedNCT00806013
Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide
Study the Effects of CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide in Healthy Chinese Subject
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (actual)
- Sponsor
- Chinese Academy of Sciences · Other Government
- Sex
- Male
- Age
- 21 Years – 27 Years
- Healthy volunteers
- Accepted
Summary
The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.
Detailed description
Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treatment.
Conditions
Timeline
- Start date
- 2008-08-01
- Completion
- 2008-12-01
- First posted
- 2008-12-10
- Last updated
- 2010-01-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00806013. Inclusion in this directory is not an endorsement.